Novo NordiskNovo Nordisk ranks as best-in-class in healthcare - one of 18 global supersectors - in Dow Jones Sustainability Indexes, the world's leading indexes for sustainability-driven investment portfolios. This ranking, effective at the opening of equity markets on 24 September 2007, is a result of the latest global analysis of corporate sustainability leadership, based on a thorough analysis of companies' economic, environmental and social performance.

The analysis concludes that "Novo Nordisk is the leading company in terms of sustainability in the pharmaceutical industry. Sustainability is an integral part of its corporate strategy and business organisation." Novo Nordisk's performance is found to be particularly strong in the social dimension – human capital development, corporate citizenship/philanthropy, social reporting, animal testing and bioethics. Also the company's responsible sourcing, environmental management and climate strategy achieve high scores.

"This rating is important for us. Our ambition is to be the leading healthcare company in terms of sustainability, and we regard the ranking in Dow Jones Sustainability Indexes as recognition of the results we have achieved so far," says Lise Kingo, executive vice president and chief of staffs, Novo Nordisk.

The indexes, which currently comprise USD 5.6 billion assets under management, are used as a tool by asset managers in 15 countries to guide their investment decisions.

The Dow Jones Sustainability Indexes follow a best-in-class approach and include the sustainability leaders from each industry on a global and regional level, respectively. The annual review is based on a thorough analysis of corporate economic, environmental and social performance, assessing issues such as corporate governance, risk management, branding, climate change, supply chain standards and labour practices.

Novo Nordisk has been a component of the Dow Jones Sustainability Indexes every year since the launch in 1999.

About Novo Nordisk
Novo Nordisk is a healthcare company and a world leader in diabetes care. The company has the broadest diabetes product portfolio in the industry, including the most advanced products within the area of insulin delivery systems. In addition, Novo Nordisk has a leading position within areas such as haemostasis management, growth hormone therapy and hormone replacement therapy. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession and society. With headquarters in Denmark, Novo Nordisk employs approximately 25,350 employees in 79 countries, and markets its products in 179 countries. Novo Nordisk's B shares are listed on the stock exchanges in Copenhagen and London. Its ADRs are listed on the New York Stock Exchange under the symbol ‘NVO’. For more information, visit